{"id":"optimized-background-arv","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lipid abnormalities"},{"rate":null,"effect":"Mitochondrial toxicity"}]},"_chembl":{"chemblId":"CHEMBL4862963","moleculeType":"Small molecule","molecularWeight":"812.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Background ARV regimens are customized antiretroviral therapy combinations chosen after genotypic or phenotypic resistance testing to ensure the patient's HIV strain remains susceptible to the selected agents. Hoffmann-La Roche's optimized approach integrates resistance data with pharmacokinetic considerations and individual patient factors to improve treatment outcomes and reduce the risk of virological failure and resistance development.","oneSentence":"Optimized background ARV refers to a tailored combination of antiretroviral drugs selected based on individual patient resistance testing and treatment history to maximize viral suppression in HIV infection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:41:49.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with documented resistance"}]},"trialDetails":[{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT04648280","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-06-30","conditions":"HIV Infections With Multi Drug Resistant Virus","enrollment":60},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT04406727","phase":"PHASE3","title":"UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"United BioPharma","startDate":"2023-12-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT01504841","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-14","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT00615134","phase":"PHASE2","title":"INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT00488059","phase":"PHASE4","title":"A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"HIV Infections","enrollment":29},{"nctId":"NCT01026727","phase":"PHASE2","title":"A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy","status":"TERMINATED","sponsor":"Myrexis Inc.","startDate":"2009-11","conditions":"HIV Infections","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Optimized background ARV","genericName":"Optimized background ARV","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Optimized background ARV refers to a tailored combination of antiretroviral drugs selected based on individual patient resistance testing and treatment history to maximize viral suppression in HIV infection. Used for HIV-1 infection in treatment-experienced patients with documented resistance.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}